A single-arm phase II-study to confirm efficacy and feasibility of tarlatamab treatment in patients with extensive stage small-cell lung cancer with poor performance status (SPACE-T) [without IMPD-Q]

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-522437-65-00

Acronym

AIO-TRK-0624

Enrollment

Registered

2025-10-31

Start date

Unknown

Completion date

Unknown

Last updated

2025-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

small-cell lung cancer

Brief summary

Overall survival (OS) rate at 12 months

Detailed description

Overall survival (OS), Progression-free survival (PFS), Objective response rate (ORR) (RECIST v1.1), intracranial ORR (RECIST v1.1), Rate of patients tolerating tarlatamab until first disease assessment, Time to next-line systemic therapy, Safety and tolerability, Quality of life: o EORTC-QLQ-C30 o PRO CTCAE

Interventions

DRUGTarlatamab

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Overall survival (OS) rate at 12 months	—

Secondary

Measure	Time frame
Overall survival (OS), Progression-free survival (PFS), Objective response rate (ORR) (RECIST v1.1), intracranial ORR (RECIST v1.1), Rate of patients tolerating tarlatamab until first disease assessment, Time to next-line systemic therapy, Safety and tolerability, Quality of life: o EORTC-QLQ-C30 o PRO CTCAE	—

Countries

Germany

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026